系统性免疫炎症指数对扩散型大B细胞淋巴瘤患者的预后和临床病理影响:元分析

Zaijing Fan1, Lihong Shou2

  • 1Clinical Laboratory, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, The Fifth School of Clinical Medicine Zhejiang Chinese Medical University, Huzhou, Zhejiang, China.

PubMed
概括

系统性免疫炎症指数 (SII) 是扩散型大B细胞淋巴瘤 (DLBCL) 的显著预后标志物. 较高的SII水平预测DLBCL患者的整体存活率和无进展存活率较差.